- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
21 result(s) found for: Preservatives.
Displaying page 1 of 2.
EudraCT Number: 2006-001308-35 | Sponsor Protocol Number: EB-UGI 01 | Start Date*: 2006-05-04 |
Sponsor Name:The Finsen Center, Rigshospitalet | ||
Full Title: A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapy | ||
Medical condition: Histologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histologic... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000182-10 | Sponsor Protocol Number: CBI-GBM-01 | Start Date*: 2006-05-04 |
Sponsor Name:Rigshospitalet, Finsen Center | ||
Full Title: A phase II trial with cetuximab, bevacizumab and irinotecan for patients with malignant glioblastomas and progression after radiation therapy and temozolamid | ||
Medical condition: Recurrent or progressive primary GBM in patients with performance status (PS) 0-2. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-003679-40 | Sponsor Protocol Number: BEV-CCI-779-GBM-02 | Start Date*: 2008-09-03 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: A phase II study of temsirolimus and bevacizumab in recurrent glioblastoma multiforme | |||||||||||||
Medical condition: Glioblastoma multiforme and progression after prior VEGF-directed therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003326-13 | Sponsor Protocol Number: BTI-011-EC/15/QUER | Start Date*: 2016-01-05 |
Sponsor Name:BTI Biotechnology Institute I mas D | ||
Full Title: Randomized, parallel groups, multicenter and blind to evaluators clinical trial, to evaluate the efficacy and safety of PRGF-Endoret eye drops, in patients with stage 2 and 3 neurotrophic keratitis. | ||
Medical condition: Neurotrophic Keratitis (NK) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005468-14 | Sponsor Protocol Number: OPHT-081214 | Start Date*: 2015-02-24 | |||||||||||
Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology | |||||||||||||
Full Title: Latanoprost preserved versus unpreserved: effect on tear film thickness as measured with OCT | |||||||||||||
Medical condition: glaucoma and ocular hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006011-74 | Sponsor Protocol Number: BI-Brain-01 | Start Date*: 2007-02-01 |
Sponsor Name:Rigshospitalet | ||
Full Title: A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy | ||
Medical condition: Primary malignant brain tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000767-28 | Sponsor Protocol Number: 20061 | Start Date*: 2006-09-29 |
Sponsor Name:Vienna Medical University | ||
Full Title: Standardisierte Verlaufsbeobachtung von Patienten mit intrathekalem S(+)-Ketamin | ||
Medical condition: Intrathecal S(+)-ketamine is a potent option in the treatment of chronic severe neuropathic pain in cancer patients refractory to conventional therapeutic strategies (Benrath et al. 2005). However,... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001647-46 | Sponsor Protocol Number: IIBSP-END-2018-96 | Start Date*: 2020-01-20 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
Full Title: Evaluation of the regenerative efficacy of Endoret® (PRGF-Plasm Rich in Growth Factors) on the ocular surface of glaucoma patients treated chronically with ocular hypotensive drugs | ||
Medical condition: Glaucoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021407-24 | Sponsor Protocol Number: BIBF1120-GBM | Start Date*: 2010-11-09 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Phase II study of BIBF 1120 in recurrent Glioblastoma multiforme | |||||||||||||
Medical condition: Relapsed glioblastoma multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001049-42 | Sponsor Protocol Number: | Start Date*: 2012-07-05 |
Sponsor Name:Department of Oncology, Rigshospitalet | ||
Full Title: MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme | ||
Medical condition: Recurrent Glioblastoma multiforme | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003426-24 | Sponsor Protocol Number: GLC02-19 | Start Date*: 2020-02-13 | |||||||||||
Sponsor Name:IRCCS FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA ONLUS | |||||||||||||
Full Title: 24-hour efficacy and tolerability of the tafluprost-timolol fixed association without preservatives in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with B... | |||||||||||||
Medical condition: Glaucoma or ocular hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001662-35 | Sponsor Protocol Number: BTIIMD-02-EC/22/GLAUCOMA | Start Date*: 2022-08-18 |
Sponsor Name:BTI I MAS D S.L. | ||
Full Title: Randomized, double-blind, parallel group clinical trial to evaluate the efficacy and safety of PRGF eye drops as a treatment for dry eye disease in patients with glaucoma | ||
Medical condition: Dry eye disease in patients with glaucoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019975-30 | Sponsor Protocol Number: 35131 | Start Date*: 2010-08-24 | ||||||||||||||||
Sponsor Name:University Medical Center, Johannes Gutenberg-University Mainz | ||||||||||||||||||
Full Title: Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops an... | ||||||||||||||||||
Medical condition: Patients with glaucoma requiring trabeculectomy (filtration surgery) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001793-36 | Sponsor Protocol Number: GTX-102-001 | Start Date*: 2023-04-26 |
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS) | ||
Medical condition: Angelman Syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Ongoing) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000172-26 | Sponsor Protocol Number: 1301-PG-PSC-203 | Start Date*: 2014-06-26 | |||||||||||
Sponsor Name:Laboratorios LETI S.L.U | |||||||||||||
Full Title: A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatoph... | |||||||||||||
Medical condition: Allergic rhinitis or rihinoconjuntivitis, with controlled allergic asthma due to D. pteronyssinus and Blomia tropicalis or Lepidoglyphus destructor sensitization. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001571-31 | Sponsor Protocol Number: 6078-PG-PSC-204 | Start Date*: 2014-10-23 | |||||||||||
Sponsor Name:Laboratorios LETI, S.L. Unipersonal | |||||||||||||
Full Title: A randomized (open-label design), parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% GrassesMix, 33% Olea europaea and 33% Salsola kali... | |||||||||||||
Medical condition: Patients with allergic rhinitis or rhinoconjunctivitis, with or without asthma, controlled by triple sensitization to grass pollen, Olea europaea and Salsola kali, susceptible to treatment with imm... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018562-23 | Sponsor Protocol Number: 6078-PG-PSC-169 | Start Date*: 2010-09-15 | |||||||||||||||||||||
Sponsor Name:LETI Pharma GmbH | |||||||||||||||||||||||
Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivi... | |||||||||||||||||||||||
Medical condition: Allergic rhinitis and/or allergic rhinoconjunctivitis with or without intermittent asthma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: CZ (Prematurely Ended) BG (Ongoing) HU (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004732-19 | Sponsor Protocol Number: 6043-PG-PSC-206 | Start Date*: 2015-07-20 | |||||||||||||||||||||
Sponsor Name:LETI Pharma GmbH | |||||||||||||||||||||||
Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum versus Placebo in Patients with Allergic Rhinitis and/or R... | |||||||||||||||||||||||
Medical condition: Allergic Rhinitis and / or Rhinoconjunctivitis with or without Intermittent Asthma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) PL (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000416-28 | Sponsor Protocol Number: 6043-PG-PSC-192 | Start Date*: 2012-08-22 | |||||||||||||||||||||
Sponsor Name:LETI Pharma GmbH | |||||||||||||||||||||||
Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivi... | |||||||||||||||||||||||
Medical condition: Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000160-34 | Sponsor Protocol Number: BECRO/OV/BRIMTIM | Start Date*: 2015-06-29 | |||||||||||||||||||||
Sponsor Name:OmniVision GmbH | |||||||||||||||||||||||
Full Title: Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Formulation of 0.2% Brimonidin... | |||||||||||||||||||||||
Medical condition: Open angle glaucoma or ocular hypertension. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
